India Pharma Outlook Team | Tuesday, 13 October 2026
The Keytruda biosimilar developed by Formycon and licensed to Zydus Lifesciences has reached a significant US regulatory milestone, with the US FDA accepting its application for review on October 13, 2026.
The proposed medicine, FYB206, is a biosimilar to pembrolizumab, Merck’s widely used cancer immunotherapy.
The application was submitted in the third quarter of 2026, and a regulatory decision could come in the third quarter of 2027.
However, the development is notable for more than its progress towards approval: FYB206 advanced without a comparative Phase III efficacy trial, following a development pathway agreed with the FDA.
The case highlights how evolving regulatory expectations could change the cost and timelines of developing complex oncology biosimilars.
Formycon said it agreed with the FDA in February 2025 that FYB206 would not require a comparative Phase III efficacy trial.
Instead, its development program relied on analytical and functional comparability evidence alongside a pivotal pharmacokinetic study.
In February 2026, Formycon reported that the Dahlia pharmacokinetic study met its primary objective, demonstrating pharmacokinetic equivalence between FYB206 and the reference medicine.
In October 2025, the FDA issued draft guidance proposing that comparative efficacy studies would generally no longer be necessary for therapeutic protein biosimilars when other evidence adequately establishes biosimilarity.
This development also highlights how biosimilar development, clinical research, and pharmaceutical regulatory pathways are evolving to support the approval of complex biologic medicines.
The FDA's proposal reflects the growing importance of analytical evidence in evaluating whether a proposed biosimilar is sufficiently similar to its reference product.
However, this does not mean that clinical studies are no longer required for every biosimilar. The evidence needed depends on the individual product and the scientific questions that remain unresolved.
Also Read: Building Sustainable Pharma Growth through Ethical Marketing Practices
Comparative efficacy trials can require substantial investment and time. Formycon said avoiding a Phase III efficacy trial reduced the investment required for FYB206 by an estimated high double-digit million euros.
For developers, a streamlined pathway could offer several advantages:
For Indian pharmaceutical companies, these developments are particularly relevant as competition expands into complex biologics and oncology treatments.
Nevertheless, streamlined development does not remove the need to demonstrate biosimilarity, product quality, safety, and appropriate clinical evidence.
Under an exclusive licensing and supply agreement signed in December 2025, Formycon is responsible for completing development, preparing regulatory submissions and supplying FYB206.
Zydus holds exclusive commercialization rights in the United States and Canada.
The arrangement combines Formycon's biosimilar development capabilities with Zydus' commercial presence in North America.
Formycon has also partnered the candidate with other companies for selected international markets.
This partnership model illustrates how pharmaceutical companies can combine specialized biologics development with regional commercialization expertise to compete in technically demanding markets.
The commercial opportunity is substantial. The Keytruda biosimilar and its subcutaneous formulation, Keytruda Qlex, generated combined worldwide sales of USD 31.7 billion in 2025, according to Formycon's announcement.
Yet FDA acceptance is not equivalent to approval or immediate market availability. FYB206 must complete regulatory review, and commercialization remains subject to intellectual-property considerations.
The timing of market entry, manufacturing capacity, pricing, and adoption by healthcare providers will influence whether a biosimilar translates into greater patient access.
For Zydus, the next milestone is therefore not simply a regulatory decision. It is whether FYB206 can progress through review and overcome the remaining barriers to commercialization.
Its development pathway also offers a practical example of how evolving biosimilar regulations could reshape competition in oncology medicines.
.jpg)
